Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

MLA

Clumeck, N., et al. “Simplification with Abacavir-Based Triple Nucleoside Therapy versus Continued Protease Inhibitor-Based Highly Active Antiretroviral Therapy in HIV-1-Infected Patients with Undetectable Plasma HIV-1 RNA.” AIDS (London, England), vol. 15, no. 12, Aug. 2001, pp. 1517–26. EBSCOhost, https://doi.org/10.1097/00002030-200108170-00009.

APA

Clumeck, N., Goebel, F., Rozenbaum, W., Gerstoft, J., Staszewski, S., Montaner, J., Johnson, M., Gazzard, B., Stone, C., Athisegaran, R., & Moore, S. (2001). Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS (London, England), 15(12), 1517–1526. https://doi.org/10.1097/00002030-200108170-00009

Chicago

Clumeck, N, F Goebel, W Rozenbaum, J Gerstoft, S Staszewski, J Montaner, M Johnson, et al. 2001. “Simplification with Abacavir-Based Triple Nucleoside Therapy versus Continued Protease Inhibitor-Based Highly Active Antiretroviral Therapy in HIV-1-Infected Patients with Undetectable Plasma HIV-1 RNA.” AIDS (London, England) 15 (12): 1517–26. doi:10.1097/00002030-200108170-00009.